OCS-05, an experimental medication that Oculis is developing to treat acute optic neuritis, a common symptom of multiple sclerosis (MS) that can lead to vision loss, was well tolerated and ...

OCS-05 demonstrates safety and efficacy in treating acute optic neuritis, receiving FDA IND clearance for clinical development in the U.S. Small sample size of only 36 patients in the Phase 2 ...

Subjects with recent onset of unilateral acute optic neuritis were randomised in the trial. Credit: PeopleImages.com – Yuri A/Shutterstock. Oculis Holding has reported that the randomised Phase II ...